Study Links Alzheimer’s Disease and Obesity
A recent study conducted by researchers at Washington University School of Medicine in St. Louis revealed a significant connection between Alzheimer’s disease and obesity. They found that biomarkers related to Alzheimer’s disease accelerate at a rate of 95% faster in obese individuals compared to their non-obese counterparts.
This research, which was shared on Tuesday at the Radiological Society of North America’s annual meeting in Chicago, analyzed five years’ worth of data from 407 participants involved in the Alzheimer’s Disease Neuroimaging Initiative. This included medical imaging data, such as PET scans, along with various blood samples.
The team honed in on the relationship between Alzheimer’s biomarkers and body mass index (BMI). Initially, heavier individuals exhibited higher blood volume, leading to a temporary association where a higher BMI correlated with lower blood biomarkers for Alzheimer’s due to blood dilution.
As researchers continued monitoring participants, they noted that those classified as obese displayed a more pronounced burden of Alzheimer’s disease. Further analyses linked the accumulation of amyloid plaques—key markers of the most common form of dementia—with these findings.
Dr. Sohail Mohammadi, the lead author of the study, highlighted how obesity was continually correlated with increasing Alzheimer’s-related issues over the five-year period. He expressed surprise at how sensitive the blood biomarkers were, noting they detected subtle changes more effectively than brain imaging.
Dr. Cyrus Raj, a senior author on the study, emphasized that the progression of Alzheimer’s disease is significantly impacted by various medical conditions throughout the body, such as obesity. He stressed maintaining overall physical health to help support brain health.
Moreover, recent clinical trials are exploring the potential of GLP-1 drugs like semaglutide (Ozempic) to slow cognitive decline in those diagnosed with early Alzheimer’s. While results from a recent trial did not find efficacy for treating Alzheimer’s directly, there is hope that further research may reveal ways to prevent the disease by addressing obesity early in life.
One area where the study shows a limitation is that not all types of body fat pose the same risk for Alzheimer’s. Dr. Mohammadi noted that previous research indicated abdominal fat might be primarily responsible for the brain effects linked to obesity. He advocated for future studies to differentiate between types of fat rather than treating obesity as a uniform issue.
Dr. Mark Siegel, a senior medical analyst who wasn’t part of the study, expressed that the findings resonate well with existing knowledge of how obesity leads to inflammation and insulin resistance, both of which are key factors in Alzheimer’s disease development.
However, the study does come with some limitations. Its sample size is relatively small and may not represent broader populations, plus BMI does not capture distinctions between fat and muscle mass or variations in fat distribution which could influence Alzheimer’s risk. The findings reflect associations rather than establishing direct causation between obesity and Alzheimer’s disease progression.
This study underscores the need for larger and more diverse research efforts, aiming to follow participants over longer durations to delve deeper into these connections.
